Barrington analyst Kevin Steinke lowered the firm’s price target on Cross Country Healthcare to $29 from $35 and keeps an Outperform rating on the shares. The analyst says the company reported “solid” Q2 results relative to expectations. Due to the slower than expected rebound in demand, guidance for Q3 was modestly lower than expectations, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CCRN: